8 Rheumatology Headlines You Missed in January 2026

January opened 2026 with a strong signal that rheumatology is entering a more targeted, mechanism-driven era, as multiple late-stage trials and regulatory actions highlighted progress across systemic autoimmune, inflammatory, and musculoskeletal diseases. Advances in FcRn inhibition featured prominently, with positive data for nipocalimab in systemic lupus erythematosus and expanding evidence for efgartigimod across seronegative myasthenia gravis populations, alongside phase 3 support for a more flexible, subcutaneous formulation of anifrolumab that aligns with evolving lupus treatment goals around remission and steroid reduction.

Beyond immunology, the month’s top news underscored a growing emphasis on disease modification, prevention, and holistic care. Combination strategies targeting both inflammation and comorbidity burden improved outcomes in psoriatic arthritis with obesity, while long-term data in rheumatoid arthritis prevention raised important questions about who stands to benefit most from early intervention. Regulatory milestones—including a first-in-class osteoarthritis risk–reduction claim for the BEAR Implant and Breakthrough Therapy designation for a potential first targeted Sjögren disease therapy—rounded out a month that reflected both therapeutic innovation and a shifting standard of care across rheumatology.

Check out this January 2026 rheumatology month in review for a recap of HCPLive’s coverage of the top news and research from the past few weeks:

1. Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point

Nipocalimab significantly reduced disease activity in adults with systemic lupus erythematosus, meeting the primary SRI-4 endpoint in the phase 2b JASMINE trial and supporting plans for phase 3 development. The FcRn-blocking monoclonal antibody was well tolerated with no new safety signals, reinforcing its potential as an immunoselective, steroid-sparing option in autoantibody-driven SLE.

2. Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease Control

Combination therapy with ixekizumab and tirzepatide demonstrated superior efficacy to ixekizumab alone in adults with active psoriatic arthritis and obesity, delivering significantly higher rates of ACR50 response alongside meaningful weight loss in the phase 3b TOGETHER-PsA trial. The findings suggest that addressing obesity pharmacologically can directly improve PsA disease control, supporting an integrated treatment approach for a historically difficult-to-treat population.

3. Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus

Subcutaneous anifrolumab met its primary endpoint in the phase 3 TULIP-SC trial, significantly improving disease control, remission rates, and steroid-sparing outcomes in adults with moderate-to-severe SLE when added to standard therapy. The findings support a more flexible, patient-administered option that aligns with evolving lupus guidelines emphasizing early biologic use, DORIS-defined remission, and reduced corticosteroid exposure.

4. FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis

The FDA has accepted argenx’s sBLA for intravenous efgartigimod alfa-fcab to treat adults with AChR-antibody–seronegative generalized myasthenia gravis, granting Priority Review with a PDUFA date of May 10, 2026. The filing is supported by phase 3 ADAPT SERON data showing significant improvements in MG-ADL scores, positioning efgartigimod to potentially expand targeted FcRn inhibition to a broader MG population regardless of antibody status.

5. FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL Reconstruction

The FDA has granted 510(k) clearance to update labeling for Miach Orthopedics’ BEAR Implant to include a reduced risk of radiographically confirmed post-traumatic osteoarthritis compared with ACL reconstruction using hamstring autograft, marking a first-in-class claim in sports medicine. The decision was supported by 6-year pooled BEAR I and II data showing a sixfold lower PTOA rate and a –27.7% absolute reduction versus ACL reconstruction, highlighting the long-term joint preservation potential of biologic ACL repair.

6. FDA Grants Breakthrough Therapy Designation to Ianalumab, First Potential Sjögren’s Targeted Therapy

The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren disease, positioning it as a potential first-in-class targeted therapy with regulatory submissions planned for early 2026. The designation is supported by phase 3 NEPTUNUS-1 and -2 data showing statistically significant improvements in systemic disease activity and patient-reported outcomes with monthly dosing versus placebo.

7. Abatacept May Delay Progression from At-Risk to Rheumatoid Arthritis

Long-term follow-up from the APIPPRA program suggests abatacept can delay progression to rheumatoid arthritis in at-risk individuals for several years, with a modest but statistically significant extension of arthritis-free survival observed through 4 years. However, the protective effect appears to wane after treatment cessation, with minimal differences between groups beyond 1–2 years, highlighting the need to better identify which high-risk patients may derive sustained benefit from preventive therapy.

8. Efgartigimod Offers Benefit in Seronegative Generalized Myasthenia Gravis

Efgartigimod significantly improved disease severity, daily functioning, and quality-of-life measures in patients with double-seronegative generalized myasthenia gravis in a 6-month prospective study, addressing a major evidence gap in this treatment-resistant population. Improvements in MGII and MG-ADL exceeded clinically meaningful thresholds, with a high responder rate and a favorable safety profile, supporting FcRn inhibition as a promising option beyond antibody-positive MG.